Compositions and methods for inhibiting expression of ADAMTS-5 and ADAM17
AssigneesGuangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou Ribobio Co., Ltd.
InventorsBill Biliang Zhang, Micky Daniel Tortorella, Zhe Wang, Xiuqun Yang, Qiuyun Wang
Life of this patent
Estimating the term…
Abstract
Provided are siRNAs or chemically-modified siRNAs targeted against ADAMTS-5 or ADAM17 for inhibiting the expression of ADAMTS-5 or ADAM17. Use of the siRNAs for treating an ADAMTS-5 or ADAM17 associated disease, such as arthritis and other inflammation-related diseases, by injecting the siRNAs or preparations comprising the siRNAs into an articular cavity of the patient, are also provided.
Claims7
A pharmaceutical composition comprising at least one siRNA targeted against ADAMTS-5, and at least one siRNA targeted against ADAM17, and optionally a pharmaceutically acceptable carrier, wherein the sense strand of the double-stranded siRNA targeted against ADAMTS-5 comprises a nucleotide sequence of SEQ ID NO:
- 3, and the antisense strand of double-stranded siRNA targeted against ADAMTS-5 comprises a nucleotide sequence of SEQ ID NO:
- 4, and wherein the sense strand of the double-stranded siRNA targeted against ADAM17 comprises a nucleotide sequence of SEQ ID NO:
- 7, and the antisense strand of the double-stranded siRNA targeted against ADAM17 comprises a nucleotide sequence of SEQ ID NO:
- 8.
Dependencies are inferred from the claim text.